Abstract Immune checkpoint blockade (ICB) has transformed cancer therapy, yet clinical benefit remains highly heterogeneous. Although the intratumoral immune landscape is central to understanding ICB efficacy, peripheral T-cell clonal dynamics highlight the importance of immune processes beyond the tumor microenvironment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile